164 related articles for article (PubMed ID: 35846884)
1. GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer.
Chen C; Wu B; Wang M; Chen J; Huang Z; Shi JS
PeerJ; 2022; 10():e12728. PubMed ID: 35846884
[TBL] [Abstract][Full Text] [Related]
2. CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.
Zhao S; Chen C; Chang K; Karnad A; Jagirdar J; Kumar AP; Freeman JW
Clin Cancer Res; 2016 Nov; 22(22):5592-5604. PubMed ID: 27267855
[TBL] [Abstract][Full Text] [Related]
3. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit.
Takehara A; Hosokawa M; Eguchi H; Ohigashi H; Ishikawa O; Nakamura Y; Nakagawa H
Cancer Res; 2007 Oct; 67(20):9704-12. PubMed ID: 17942900
[TBL] [Abstract][Full Text] [Related]
4. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
[TBL] [Abstract][Full Text] [Related]
5. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca
Jiang SH; Zhu LL; Zhang M; Li RK; Yang Q; Yan JY; Zhang C; Yang JY; Dong FY; Dai M; Hu LP; Li J; Li Q; Wang YH; Yang XM; Zhang YL; Nie HZ; Zhu L; Zhang XL; Tian GA; Zhang XX; Cao XY; Tao LY; Huang S; Jiang YS; Hua R; Qian Luo K; Gu JR; Sun YW; Hou S; Zhang ZG
Gut; 2019 Nov; 68(11):1994-2006. PubMed ID: 30826748
[TBL] [Abstract][Full Text] [Related]
6. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
7. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
8. KDM5 family of demethylases promotes CD44-mediated chemoresistance in pancreatic adenocarcinomas.
Wang D; Zhang Y; Liao Z; Ge H; Güngör C; Li Y
Sci Rep; 2023 Oct; 13(1):18250. PubMed ID: 37880235
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
10. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
Hong SP; Wen J; Bang S; Park S; Song SY
Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching.
Chen C; Zhao S; Zhao X; Cao L; Karnad A; Kumar AP; Freeman JW
Cell Death Dis; 2022 Aug; 13(8):682. PubMed ID: 35931675
[TBL] [Abstract][Full Text] [Related]
12. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
13. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
14. The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells.
Tsubouchi K; Minami K; Hayashi N; Yokoyama Y; Mori S; Yamamoto H; Koizumi M
J Radiat Res; 2017 Nov; 58(6):816-826. PubMed ID: 29106581
[TBL] [Abstract][Full Text] [Related]
15. LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
Zhu YX; Li CH; Li G; Feng H; Xia T; Wong CH; Fung FKC; Tong JH; To KF; Chen R; Chen Y
Cell Mol Gastroenterol Hepatol; 2020; 10(4):811-828. PubMed ID: 32615164
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
17. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
18. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
19. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]